Skyhawk news

Browse:

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression

April 22, 2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration
Read
2 min read
April 22, 2024
Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D
Read
1 min read
February 28, 2024
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease
SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform.
Read
2 min read
December 5, 2023
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, Inc. today announced it recently dosed its first patient in a Phase 1/1b study of the Company’s proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumor
Read
3 min read
May 17, 2023
Drugging RNA
Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success.
Read
1 min read